trial · primary record
Ublituximab
Multiple Sclerosis
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 350 |
| Primary completion | 2029-05-30 |
| Primary endpoint | Part 2: Area under the curve (AUC) at Steady State [AUCss] of Ublituximab |
| Registry ID | NCT07503873 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:50.903Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07503873
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ublituximab · compound